• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Berkeley Lights Inc.

    3/29/23 4:02:49 PM ET
    $BLI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BLI alert in real time by email
    SC 13G 1 d493488dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    (Amendment No.     )*

     

     

    PhenomeX Inc.

    (Name of Issuer)

    Common Stock, par value $0.00005

    (Title of Class of Securities)

    84310101

    (CUSIP Number)

    March 21, 2023

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 84310101   13G

     

      1    

      Names of Reporting Persons

     

      Northpond Ventures, LP

      2  

      Check the appropriate box if a member of a Group

      (a)  ☒        (b)  ☐

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5    

      Sole Voting Power

     

      0

       6  

      Shared Voting Power

     

      4,117,272

       7  

      Sole Dispositive Power

     

      0

       8  

      Shared Dispositive Power

     

      4,117,272

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      4,117,272

    10  

      Check box if the aggregate amount in row (9) excludes certain shares

     

      ☐

    11  

      Percent of class represented by amount in row (9)

     

      4.3%

    12  

      Type of Reporting Person

     

      PN

     

    Page 2 of 12


    CUSIP No. 84310101   13G

     

      1    

      Names of Reporting Persons

     

      Northpond Ventures GP, LLC

      2  

      Check the appropriate box if a member of a Group

      (a)  ☒        (b)  ☐

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5    

      Sole Voting Power

     

      0

       6  

      Shared Voting Power

     

      4,117,272

       7  

      Sole Dispositive Power

     

      0

       8  

      Shared Dispositive Power

     

      4,117,272

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      4,117,272

    10  

      Check box if the aggregate amount in row (9) excludes certain shares

     

      ☐

    11  

      Percent of class represented by amount in row (9)

     

      4.3%

    12  

      Type of Reporting Person

     

      OO

     

    Page 3 of 12


    CUSIP No. 84310101   13G

     

      1    

      Names of Reporting Persons

     

      Northpond Capital, LP

      2  

      Check the appropriate box if a member of a Group

      (a)  ☒        (b)  ☐

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5    

      Sole Voting Power

     

      0

       6  

      Shared Voting Power

     

      1,273,548

       7  

      Sole Dispositive Power

     

      0

       8  

      Shared Dispositive Power

     

      1,273,548

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,273,548

    10  

      Check box if the aggregate amount in row (9) excludes certain shares

     

      ☐

    11  

      Percent of class represented by amount in row (9)

     

      1.3%

    12  

      Type of Reporting Person

     

      PN

     

    Page 4 of 12


    CUSIP No. 84310101   13G

     

      1    

      Names of Reporting Persons

     

      Northpond Capital GP, LLC

      2  

      Check the appropriate box if a member of a Group

      (a)  ☒        (b)  ☐

     

      3  

      Sec Use Only

     

      4  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5    

      Sole Voting Power

     

      0

       6  

      Shared Voting Power

     

      1,273,548

       7  

      Sole Dispositive Power

     

      0

       8  

      Shared Dispositive Power

     

      1,273,548

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,273,548

    10  

      Check box if the aggregate amount in row (9) excludes certain shares

     

      ☐

    11  

      Percent of class represented by amount in row (9)

     

      1.3%

    12  

      Type of Reporting Person

     

      OO

     

    Page 5 of 12


    CUSIP No. 84310101   13G

     

      1    

      Names of Reporting Persons

     

      Michael P. Rubin

      2  

      Check the appropriate box if a member of a Group

      (a)  ☒        (b)  ☐

     

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization

     

      United States of America

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5    

      Sole Voting Power

     

      0

       6  

      Shared Voting Power

     

      5,390,820

       7  

      Sole Dispositive Power

     

      0

       8  

      Shared Dispositive Power

     

      5,390,820

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      5,390,820

    10  

      Check box if the aggregate amount in row (9) excludes certain shares

     

      ☐

    11  

      Percent of class represented by amount in row (9)

     

      5.6%

    12  

      Type of Reporting Person

     

      IN

     

    Page 6 of 12


    CUSIP No. 84310101   13G

     

    Item 1.

     

    (a)

    Name of Issuer:

    PhenomeX Inc. (the “Issuer”)

     

    (b)

    Address of Issuer’s Principal Executive Offices:

    5858 Horton Street, Emeryville, Suite 320, CA 94608

     

    Item 2.

     

    (a)

    Name of Person Filing:

    The names of the persons filing this Schedule 13G (collectively, the “Reporting Persons”) are:

    Northpond Ventures, LP;

    Northpond Ventures GP, LLC;

    Northpond Capital, LP,

    Northpond Capital GP, LLC;

    Michael P. Rubin.

     

    (b)

    Address of Principal Business Office or, if None, Residence:

    The business address of each of the Reporting Persons is c/o Northpond Ventures, LLC, 7500 Old Georgetown Road, Suite 800, Bethesda, MD 20814.

     

    (c)

    Citizenship: See Row 4 of cover page for each Reporting Person.

     

    (d)

    Title and Class of Securities: Common Stock, $0.0005 par value (the “Common Stock”)

     

    (e)

    CUSIP No.: 84310101

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not Applicable

     

    Item 4.

    Ownership

    The securities are held of record by Northpond Ventures, LP and Northpond Capital, LP. Northpond Ventures GP, LLC is the general partner of Northpond Ventures, LP. Northpond Capital GP, LLC is the general partner of Northpond Capital, LP. Michael Rubin is the sole managing member of Northpond Ventures GP, LLC and Northpond Capital GP, LLC.

     

      (a)

    Amount beneficially owned:

    See Row 9 of cover page for each Reporting Person.

     

    Page 7 of 12


      (b)

    Percent of Class:

    See Row 11 of cover page for each Reporting Person.

    The percentage ownership is based on 96,508,935 shares of Common Stock issued and outstanding, which is the sum of (1) 72,173,917 shares of Common Stock outstanding as of December 31, 2022 as reported in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “Commission”) on February 23, 2023 and (2) 24,335,018 shares of Common Stock estimated to have been issued to the stockholders of IsoPlexis Corporation (“IsoPlexis”), at the closing of the Issuer’s acquisition of IsoPlexis on March 21, 2023 (the “Closing”), based on 39,763,101 shares of common stock of IsoPlexis reported to be outstanding as of February 27, 2023 in the IsoPlexis Annual Report on Form 10-K filed with the Commission on March 2, 2023, multiplied by 0.6120, the exchange ratio applicable at the Closing.

     

      (c)

    Number of shares as to which such person has:

     

      (i)

    Sole power to vote or to direct the vote:

    See Row 5 of cover page for each Reporting Person.

     

      (ii)

    Shared power to vote or to direct the vote:

    See Row 6 of cover page for each Reporting Person.

     

      (iii)

    Sole power to dispose or to direct the disposition of:

    See Row 7 of cover page for each Reporting Person.

     

      (iv)

    Shared power to dispose or to direct the disposition of:

    See Row 8 of cover page for each Reporting Person.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    Not applicable.

     

    Item 6.

    Ownership of more than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

    Not applicable.

     

    Item 8.

    Identification and classification of members of the group.

    Not applicable.

     

    Page 8 of 12


    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certifications.

    By signing below each of the undersigned certifies that, to the best of its or his knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    Page 9 of 12


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in the Statement is true, complete and correct.

    Dated: March 29, 2023

     

    Northpond Ventures, LP

     

    By: Northpond Ventures GP, LLC, its general partner

    By:   /s/ Patrick Smerkers
      Name: Patrick Smerkers
      Title: Authorized Signatory
    Northpond Ventures GP, LLC
    By:   /s/ Patrick Smerkers
      Name: Patrick Smerkers
      Title: Authorized Signatory

    Northpond Capital, LP

     

    By: Northpond Capital GP, LLC, its general partner

    By:   /s/ Patrick Smerkers
      Name: Patrick Smerkers
      Title: Authorized Signatory
    Northpond Capital GP, LLC
    By:   /s/ Patrick Smerkers
      Name: Patrick Smerkers
      Title: Authorized Signatory
    Michael P. Rubin
      /s/ Michael P. Rubin

     

    Page 10 of 12


    EXHIBIT INDEX

     

    Exhibit

      

    Found on
    Sequentially
    Numbered Page

    Exhibit 1: Agreement of Joint Filing

       12

     

     

    Page 11 of 12

    Get the next $BLI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BLI

    DatePrice TargetRatingAnalyst
    8/10/2022$10.00 → $5.00Equal-Weight → Underweight
    Morgan Stanley
    8/10/2022Buy → Neutral
    BTIG Research
    8/10/2022$12.00 → $8.00Overweight → Neutral
    JP Morgan
    3/2/2022Outperform
    Cowen
    2/25/2022$20.00 → $14.00Equal-Weight
    Morgan Stanley
    2/15/2022$36.00 → $20.00Equal-Weight
    Morgan Stanley
    1/6/2022$61.00 → $12.00Buy → Hold
    Stifel
    1/6/2022Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $BLI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

      Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut

      6/24/24 4:05:00 PM ET
      $CTNM
      $IONS
      $NVS
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
      Medicinal Chemicals and Botanical Products
    • Berkeley Lights Completes Acquisition of IsoPlexis Forming PhenomeX, the Functional Cell Biology Company

      PhenomeX to begin trading under symbol (NASDAQ:CELL) EMERYVILLE, Calif., March 21, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced that it has completed its previously announced acquisition of IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health. The newly combined company has been renamed PhenomeX and its common stock will begin trading on Nasdaq under the ticker symbol "CELL" at market open tomorrow. PhenomeX is positioned to be the leading

      3/21/23 8:02:00 AM ET
      $BLI
      $ISO
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Berkeley Lights Reports Fourth Quarter and Full Year 2022 Financial Results

      EMERYVILLE, Calif., Feb. 23, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today reported financial results for the fourth quarter and full year ended December 31, 2022. Recent Highlights Achieved revenue of $78.6 million for the full year 2022, representing an 8% decrease over the prior year;Announced the acquisition agreement of IsoPlexis to create a premier functional cell biology company, PhenomeX, when the merger closes, would accelerate the transformation of Berkeley Lights from a technology platform company into a growing, profi

      2/23/23 4:23:00 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care

    $BLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Kadia Siddhartha returned 1,240,689 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Bruker Cellular Analysis, Inc. (0001689657) (Issuer)

      10/3/23 3:42:49 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chiminski John R returned 112,465 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Bruker Cellular Analysis, Inc. (0001689657) (Issuer)

      10/3/23 3:41:09 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Silvester Peter returned 64,596 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Bruker Cellular Analysis, Inc. (0001689657) (Issuer)

      10/3/23 3:32:22 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care

    $BLI
    SEC Filings

    See more
    • SEC Form 15-12G filed by Berkeley Lights Inc.

      15-12G - Bruker Cellular Analysis, Inc. (0001689657) (Filer)

      10/12/23 9:00:26 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form POSASR filed by Berkeley Lights Inc.

      POSASR - Bruker Cellular Analysis, Inc. (0001689657) (Filer)

      10/2/23 5:16:24 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form S-8 POS filed by Berkeley Lights Inc.

      S-8 POS - Bruker Cellular Analysis, Inc. (0001689657) (Filer)

      10/2/23 5:06:56 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care

    $BLI
    Financials

    Live finance-specific insights

    See more
    • Berkeley Lights Reports Fourth Quarter and Full Year 2022 Financial Results

      EMERYVILLE, Calif., Feb. 23, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today reported financial results for the fourth quarter and full year ended December 31, 2022. Recent Highlights Achieved revenue of $78.6 million for the full year 2022, representing an 8% decrease over the prior year;Announced the acquisition agreement of IsoPlexis to create a premier functional cell biology company, PhenomeX, when the merger closes, would accelerate the transformation of Berkeley Lights from a technology platform company into a growing, profi

      2/23/23 4:23:00 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Berkeley Lights to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

      EMERYVILLE, Calif., Feb. 13, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced that the Company will be reporting financial results for the fourth quarter and full year 2022 after market on Thursday, February 23, 2023. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.   Live audio of the webcast will be available on the "Investors" section of the Company's website at www.berkeleylights.com. The webcast will be archived and available for replay

      2/13/23 4:30:00 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Berkeley Lights Reports Preliminary Full Year 2022 Revenue Results

      EMERYVILLE, Calif., Jan. 9, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced preliminary unaudited revenue results for the full year ended December 31, 2022. Total revenue for the full year 2022 is expected to be in the range of $78.0 million to $78.5 million, compared to $85.4 million in 2021. Results were lower-than-expected due to a delay in several Beacon® platform placements, which are now expected in 2023, and lower revenue from partnership and services contracts. During fourth quarter 2022, we observed a tightening

      1/9/23 4:02:00 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care

    $BLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Berkeley Lights Inc. (Amendment)

      SC 13G/A - Bruker Cellular Analysis, Inc. (0001689657) (Subject)

      2/8/24 5:58:45 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Berkeley Lights Inc.

      SC 13G - PhenomeX Inc. (0001689657) (Subject)

      8/28/23 5:04:18 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Berkeley Lights Inc. (Amendment)

      SC 13G/A - PhenomeX Inc. (0001689657) (Subject)

      5/5/23 11:52:59 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care

    $BLI
    Leadership Updates

    Live Leadership Updates

    See more
    • Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

      Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut

      6/24/24 4:05:00 PM ET
      $CTNM
      $IONS
      $NVS
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
      Medicinal Chemicals and Botanical Products
    • Berkeley Lights Announces Appointment of Scott Chaplin as Chief Legal Officer

      EMERYVILLE, Calif., Sept. 19, 2022 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a leader in digital cell biology, today announced that Scott Chaplin has been named the Company's chief legal officer and corporate secretary, effective immediately. Mr. Chaplin will have overall responsibility for the corporate legal function, including contracts, governance, compliance and management of its extensive intellectual property and patent portfolio. As chief legal officer, he will serve as an adviser to the chief executive officer (CEO), Board of Directors, and senior management members.

      9/19/22 8:43:00 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Berkeley Lights Announces Appointment of Dr. Rolando Brawer as Executive Vice President, Strategy & Corporate Development

      EMERYVILLE, Calif., Aug. 1, 2022 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a leader in digital cell biology, today announced that Rolando Brawer, Ph.D. has been named executive vice president, Strategy & Corporate Development, effective immediately. In this newly created role, Dr. Brawer will lead Berkeley Lights' strategy and corporate development functions and support the Company's growth strategy through identification, assessment and execution of potential mergers, acquisitions, investments, licensing agreements, joint ventures and more. "We are thrilled to welco

      8/1/22 8:35:00 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care

    $BLI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Berkeley Lights downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Berkeley Lights from Equal-Weight to Underweight and set a new price target of $5.00 from $10.00 previously

      8/10/22 9:27:59 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Berkeley Lights downgraded by BTIG Research

      BTIG Research downgraded Berkeley Lights from Buy to Neutral

      8/10/22 7:24:20 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Berkeley Lights downgraded by JP Morgan with a new price target

      JP Morgan downgraded Berkeley Lights from Overweight to Neutral and set a new price target of $8.00 from $12.00 previously

      8/10/22 6:23:47 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care